Guangcheng Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Guangcheng Liu has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Bin Zhang
Department of Cardiology Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, 100730 Beijing, China
1 shared publication Danni Wu
Department of Cardiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China
1 shared publicationHaipeng Zhang
Department of Cardiology Medicine Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College Beijing China
1 shared publicationHao Qian
Department of Cardiology Medicine Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College Beijing China
1 shared publication- Hao Qian
Department of Cardiology Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, 100730 Beijing, China
1 shared publication Jingdai Zhang
Department of Cardiology Medicine Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College Beijing China
1 shared publication
Latest Publications
- Open Access
- 13 October 2025
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 29 (19) , e70892
Circular RNA Rftn1 Promotes Cardiac Hypertrophy In Vitro and In Vivo by Sponging miRNA‐1192 to Upregulate Tripartite Motif Protein 25 and 41
To verify the role of circular RNA circRftn1 in cardiac hypertrophy and elucidate its potential mechanism via the microRNA‐1192‐tripartite motif 25 and 41 (miR1192‐TRIM25/TRIM41) axis. A mouse model of cardiac hypertrophy was established via abdominal aortic coarctation surgery. An in vitro cell model was generated using neonatal mouse ventricular cardiomyocytes (NMVCs) co‐cultured with angiotensin II. Differentially expressed circular RNAs (circRNAs) were identified using next‐generation sequencing, and potential target microRNAs (miRNAs) and downstream messenger RNAs (mRNAs) were predicted using bioinformatic analysis. Reverse transcription quantitative polymerase chain reaction and western blotting were used to evaluate the expression of myocardial‐associated molecules at the transcriptional and translational levels, respectively. Expression of regulatory molecules was assessed after transfection with small interfering RNAs (siRNAs) or co‐culture with miRNA mimics. Dual‐luciferase reporter assays were performed to validate interactions between circRNAs and miRNAs. circRftn1 expression was significantly elevated both in vivo and in vitro. Concurrently, the expression of miR‐1192 was decreased, whereas its target mRNAs TRIM25 and TRIM41 were markedly upregulated. Knockdown of circRftn1 via siRNA transfection reversed cardiac hypertrophy and led to opposing expression trends of miR‐1192 and TRIM25/TRIM41. Dual‐luciferase reporter assays confirmed the sponge‐like interaction between circRftn1 and miR‐1192. By co‐culturing NMVCs with miR‐1192 mimics, its targets TRIM25/TRIM41 showed significant decreases. Moreover, NF‐κB signalling pathway appeared to be involved, as the expression of the p65 subunit paralleled that of circRftn1. circRftn1 may promote cardiac hypertrophy by modulating the miR‐1192‐TRIM25/TRIM41 axis and NF‐κB p65 pathway potentially serving as a downstream pathway.
- 13 October 2025
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 29 (19) , e70892
Open AccessCircular RNA Rftn1 Promotes Cardiac Hypertrophy In Vitro and In Vivo by Sponging miRNA‐1192 to Upregulate Tripartite Motif Protein 25 and 41
To verify the role of circular RNA circRftn1 in cardiac hypertrophy and elucidate its potential mechanism via the microRNA‐1192‐tripartite motif 25 and 41 (miR1192‐TRIM25/TRIM41) axis. A mouse model of cardiac hypertrophy was established via abdominal aortic coarctation surgery. An in vitro cell model was generated using neonatal mouse ventricular cardiomyocytes (NMVCs) co‐cultured with angiotensin II. Differentially expressed circular RNAs (circRNAs) were identified using next‐generation sequencing, and potential target microRNAs (miRNAs) and downstream messenger RNAs (mRNAs) were predicted using bioinformatic analysis. Reverse transcription quantitative polymerase chain reaction and western blotting were used to evaluate the expression of myocardial‐associated molecules at the transcriptional and translational levels, respectively. Expression of regulatory molecules was assessed after transfection with small interfering RNAs (siRNAs) or co‐culture with miRNA mimics. Dual‐luciferase reporter assays were performed to validate interactions between circRNAs and miRNAs. circRftn1 expression was significantly elevated both in vivo and in vitro. Concurrently, the expression of miR‐1192 was decreased, whereas its target mRNAs TRIM25 and TRIM41 were markedly upregulated. Knockdown of circRftn1 via siRNA transfection reversed cardiac hypertrophy and led to opposing expression trends of miR‐1192 and TRIM25/TRIM41. Dual‐luciferase reporter assays confirmed the sponge‐like interaction between circRftn1 and miR‐1192. By co‐culturing NMVCs with miR‐1192 mimics, its targets TRIM25/TRIM41 showed significant decreases. Moreover, NF‐κB signalling pathway appeared to be involved, as the expression of the p65 subunit paralleled that of circRftn1. circRftn1 may promote cardiac hypertrophy by modulating the miR‐1192‐TRIM25/TRIM41 axis and NF‐κB p65 pathway potentially serving as a downstream pathway.
- Open Access
- 27 May 2025
- Published by IMR Press in Reviews in Cardiovascular Medicine
- Vol. 26 (5)
Long-term Metformin Alters Gut Microbiota and Serum Metabolome in Coronary Artery Disease Patients After Percutaneous Coronary Intervention to Improve 5-year Prognoses: A Multi-omics Analysis
Background: About 20% of patients with coronary artery disease (CAD) experience adverse events within five years of undergoing percutaneous coronary intervention (PCI) for acute myocardial infarction. In these patients, the impact of metformin on long-term prognosis remains uncertain. Methods: This study enrolled 22 metformin (Met)-CAD patients with diabetes mellitus (DM) who had been administered metformin for at least six months before PCI, 14 non-Met CAD-DM patients with DM who had never taken metformin or had stopped taking metformin for a year before PCI, and 22 matched healthy controls. A 5-year follow-up was conducted to collect clinical prognosis data. Fecal 16S rRNA sequencing and serum untargeted metabolomics analyses were performed. BugBase was utilized to analyze the possible functional changes in the gut microbiome. Multi-omics analysis was conducted using Spearman’s correlation to explore the interactions between metformin, gut microbiome, serum metabolites, and clinical prognosis. Results: Metformin significantly lowered the 5-year major adverse cardiac events (MACEs) in Met CAD-DM patients. We found a higher abundance of Bacteroides coprocola, Bacteroides massiliensis, Phascolarctobacterium succinatutens, and Eubacterium coprostanoligenes in the Met CAD-DM patients, as well as an increase in hydroxy-alpha-sanshool (HAS) and decenoylcarnitine and a decrease in tridec-10-enoic acid, Z-vad-fmk (benzyloxycarbonyl–Val–Ala–Asp (OMe)–fluoromethylketone), 3,9-dimethyluric acid in blood serum. Multi-omics analysis revealed that alterations in the gut microbiome and serum metabolites are significantly associated with the 5-year prognosis of CAD-DM. Conclusions: Metformin significantly improved the 5-year prognosis of CAD patients following PCI. Metformin tended to have more positive effects on the commensal flora and metabolic profiles, which may explain its beneficial effects on cardiovascular health. This study revealed the potential associations between metformin and the gut microbiome, an associated alteration in serum metabolome, and the impact on the host immune system and metabolic pathways.
- 27 May 2025
- Published by IMR Press in Reviews in Cardiovascular Medicine
- Vol. 26 (5)
Open AccessLong-term Metformin Alters Gut Microbiota and Serum Metabolome in Coronary Artery Disease Patients After Percutaneous Coronary Intervention to Improve 5-year Prognoses: A Multi-omics Analysis
Background: About 20% of patients with coronary artery disease (CAD) experience adverse events within five years of undergoing percutaneous coronary intervention (PCI) for acute myocardial infarction. In these patients, the impact of metformin on long-term prognosis remains uncertain. Methods: This study enrolled 22 metformin (Met)-CAD patients with diabetes mellitus (DM) who had been administered metformin for at least six months before PCI, 14 non-Met CAD-DM patients with DM who had never taken metformin or had stopped taking metformin for a year before PCI, and 22 matched healthy controls. A 5-year follow-up was conducted to collect clinical prognosis data. Fecal 16S rRNA sequencing and serum untargeted metabolomics analyses were performed. BugBase was utilized to analyze the possible functional changes in the gut microbiome. Multi-omics analysis was conducted using Spearman’s correlation to explore the interactions between metformin, gut microbiome, serum metabolites, and clinical prognosis. Results: Metformin significantly lowered the 5-year major adverse cardiac events (MACEs) in Met CAD-DM patients. We found a higher abundance of Bacteroides coprocola, Bacteroides massiliensis, Phascolarctobacterium succinatutens, and Eubacterium coprostanoligenes in the Met CAD-DM patients, as well as an increase in hydroxy-alpha-sanshool (HAS) and decenoylcarnitine and a decrease in tridec-10-enoic acid, Z-vad-fmk (benzyloxycarbonyl–Val–Ala–Asp (OMe)–fluoromethylketone), 3,9-dimethyluric acid in blood serum. Multi-omics analysis revealed that alterations in the gut microbiome and serum metabolites are significantly associated with the 5-year prognosis of CAD-DM. Conclusions: Metformin significantly improved the 5-year prognosis of CAD patients following PCI. Metformin tended to have more positive effects on the commensal flora and metabolic profiles, which may explain its beneficial effects on cardiovascular health. This study revealed the potential associations between metformin and the gut microbiome, an associated alteration in serum metabolome, and the impact on the host immune system and metabolic pathways.
- Open Access
- 15 December 2024
- Published by Elsevier in Hellenic Journal of Cardiology
Prognostic value of echocardiographic cardiac chamber longitudinal strains in advanced light chain cardiac amyloidosis
- 15 December 2024
- Published by Elsevier in Hellenic Journal of Cardiology
Open AccessPrognostic value of echocardiographic cardiac chamber longitudinal strains in advanced light chain cardiac amyloidosis